<DOC>
	<DOCNO>NCT00195546</DOCNO>
	<brief_summary>Primary : To assess efficacy safety DVS-233 SR compare placebo treatment vasomotor symptom ( VMS ) associate menopause compare bleed incidence DVS-233 SR tibolone . Secondary : To assess effect DVS-233 SR tibolone change baseline weight , breast pain , health outcome indicator .</brief_summary>
	<brief_title>Study Evaluating DVS-233 SR Treatment Vasomotor Symptoms Associated With Menopause</brief_title>
	<detailed_description />
	<criteria>Postmenopausal woman age 40 65 seek treatment hot flash last natural menstrual period ( LNMP ) complete least 12 month prior screen . Minimum 7 moderate severe hot flash per day 50 per week record 7 consecutive day Body Mass Index less equal 34 kg/m2 use nomograph BMI . History , presence , suspicion estrogendependent neoplasia ; Malignancy , treatment malignancy , within previous 2 year . Active recent arterial thromboembolic disease ; History venous thromboembolism History cerebrovascular accident , stroke , transient ischemic attack Presence major depressive disorder , bipolar disorder , psychotic disorder , generalize anxiety disorder require therapy Persistent elevate blood pressure</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Menopause</keyword>
</DOC>